Wempitaz Injection is a combination antibiotic formulation containing Piperacillin 4000 mg and Tazobactam 500 mg, indicated for the treatment of serious bacterial infections caused by susceptible organisms. Piperacillin, a broad-spectrum ureidopenicillin, exerts bactericidal activity by inhibiting bacterial cell wall synthesis, while Tazobactam, a beta-lactamase inhibitor, enhances the efficacy of Piperacillin by preventing enzymatic degradation by beta-lactamase-producing bacteria. This synergistic combination is effective against a wide range of Gram-positive, Gram-negative, and anaerobic pathogens, including Pseudomonas aeruginosa. Wempitaz Injection is commonly employed in the management of complicated intra-abdominal infections, skin and soft tissue infections, urinary tract infections, respiratory tract infections, and sepsis. The drug is administered intravenously, ensuring rapid systemic distribution and optimal therapeutic levels. Dosage and duration of therapy should be tailored based on the severity of infection, patient renal function, and clinical response. Caution is advised in patients with hypersensitivity to penicillins or beta-lactamase inhibitors. Adverse effects may include hypersensitivity reactions, gastrointestinal disturbances, and hematologic abnormalities. Wempitaz Injection should be used under strict medical supervision with appropriate microbiological monitoring to prevent resistance development and ensure clinical efficacy.